What is TV TMA on a Vaginal Swab?
TV TMA is a transcription-mediated amplification test that detects Trichomonas vaginalis ribosomal RNA from a vaginal swab specimen—it is the most sensitive diagnostic method available for trichomoniasis, significantly outperforming traditional wet mount microscopy and culture. 1, 2
Test Characteristics
TV TMA (specifically the APTIMA Trichomonas vaginalis assay) is a nucleic acid amplification test (NAAT) that uses:
- Target capture specimen processing
- Transcription-mediated amplification of T. vaginalis ribosomal RNA
- Chemiluminescent probe hybridization for detection 2
This is the only FDA-cleared amplification-based assay for T. vaginalis and was approved in April 2011 2.
Performance Characteristics
The test demonstrates superior sensitivity compared to all traditional methods:
- Clinical sensitivity: 100% for vaginal swabs 3
- Clinical specificity: 99.0% for vaginal swabs 3
- Performs equally well in both symptomatic and asymptomatic women 3
In direct comparisons, TV TMA vastly outperforms older methods:
- Wet mount microscopy: only 40-80% sensitive 1
- Culture: approximately 70-82% sensitive 1, 4
- TV TMA detects twice as many infections as wet mount 5
Specimen Types Accepted
The APTIMA TV assay can use multiple specimen types 1, 2:
- Physician-collected vaginal swabs (optimal)
- Endocervical swabs
- Female urine specimens
- PreservCyt solution specimens (ThinPrep)
Transport requirements: Lab-provided transport medium, room temperature, stable for 7 days 1
Clinical Context
Why this test matters: Trichomoniasis affects an estimated 3.7 million people in the United States and is associated with serious sequelae including increased HIV acquisition risk, cervical cancer, preterm birth, and adverse pregnancy outcomes 6. Traditional wet mount microscopy misses 20-60% of infections, making NAAT testing critical for accurate diagnosis 1.
Current guidelines recommend NAATs as the preferred diagnostic method for T. vaginalis over wet mount or culture due to their superior sensitivity 1, 7. The CDC 2015 STD Treatment Guidelines specifically state that "NAATs for C. trachomatis and N. gonorrhoeae at the sites of penetration or attempted penetration are preferred for the diagnostic evaluation" and recommend "NAATs from a urine or vaginal specimen or point-of-care testing from a vaginal specimen for T. vaginalis" 7.